Howard W. Levine is a Partner in the Washington, D.C., office of Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, where his practice concentrates on patent litigation before the federal district courts and the U.S. Court of Appeals for the Federal Circuit, primarily in the areas of biotechnology and pharmaceuticals. Mr. Levine has extensive experience in cases arising from the filing of Abbreviated New Drug Applications (ANDA).
Over the last 20 years, Mr. Levine has represented both pharmaceutical and biotechnology companies in technologies ranging from the inhibition of NF-κB to genetically engineered corn. Mr. Levine was involved in litigations between Eli Lilly, Genentech, and the Regents of the University of California regarding human insulin, the first biotechnology product to be marketed. Some of the products involved in the litigations Mr. Levine served as counsel include Humulin®, Humatrope®, Zantac®, Paxil®, Evista®, Xigris®, Cymbalta®, Gemzar®, and Differin®.
Mr. Levine has conducted all aspects of pre-trial, trial, and post-trial proceedings, including appeals to the Federal Circuit and the U.S. Supreme Court. Mr. Levine lectures on the subject matter of patent law, including such topics as the written description and the patentability of different crystalline forms of drug substances.
Mr. Levine received his B.A. from Duke University and his J.D. from Georgetown University.
He is the co-author of the 2013 supplement to the Bloomberg BNA treatise Biotechnology and the Federal Circuit.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)